Shashi Kori

Shashi Kori is a neurologist and neuro-oncologist turned biotech founder, and the co-founder and CEO of Novilla Pharmaceuticals, a Cambridge-based company using a proprietary AI model to design transdermal formulations that deliver drugs to the site of action while minimizing systemic effects. Before Novilla, he spent decades building pain programs at Duke and the University of South Florida and led clinical development at GlaxoSmithKline, Allergan, MAP Pharmaceuticals and Autonomic Technologies. He partnered with Dr. Eric Fossel in 2019 to merge their drug-delivery innovations into Novilla's pipeline, led by lead candidate NOV-1776.